ArticleFrontiers in synaptic neuroscience2026
Multi-cohort meta-analysis, single-cell and Mendelian randomization analyses with experimental validation identify RHBDF2 as a shared mediator of ulcerative colitis and blood-brain barrier disruption.
Article in Frontiers in synaptic neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is increasingly associated with central nervous system comorbidities, including cognitive decline and dementia, yet the molecular mechanisms linking intestinal inflammation to brain dysfunction remain unclear. Blood-brain barrier (BBB) disruption is a plausible convergence point, but the mediators involved are largely unknown. Methods: We performed random-effects meta-analyses of five human UC bulk-transcriptome cohorts (1,130 UC and 508 control samples) and three mouse BBB-disruption (BBBD) cohorts, followed by cross-species orthologue mapping to identify shared genes. The cellular context of candidate genes was resolved by single-cell RNA-sequencing analysis of human UC colonic mucosa (GSE214695) and paired human BBB-intact/BBB-opened brain samples (GSE208074), combined with scTenifoldKnk in-silico gene knockout. Summary-data-based Mendelian randomization (SMR) integrating whole-blood cis-eQTL and FinnGen GWAS data was used to assess causal relevance to dementia. Findings were validated in dextran sulfate sodium (DSS)-induced colitis in mice preventively treated with the ADAM17 inhibitor GW280264X, with Evans blue assessment of BBB permeability. Results: Four genes-TNF, RHBDF2, PILRA and CXCL16-were significantly and concordantly up-regulated in both UC and BBBD, forming a protein-protein association module organized around the sheddase ADAM17. RHBDF2, the essential activating chaperone of ADAM17, was predominantly up-regulated in colonic epithelial cells in UC, whereas its strongest inferred regulatory impact at the human BBB mapped to endothelial cells, affecting complement, microglial and angiogenic programs. Genetically predicted higher expression of RHBDF2 and PILRA was associated with increased risk of all-cause and Alzheimer's dementia. In DSS-induced colitis, preventive administration of GW280264X attenuated intestinal inflammation, reduced cerebral Evans blue extravasation and lowered brain Rhbdf2, Adam17 and Tnfα protein levels. Conclusion: Integrative transcriptomic, genetic and experimental evidence identifies an RHBDF2-ADAM17-TNFα axis as a plausible mechanistic bridge between ulcerative colitis and blood-brain barrier disruption and a candidate therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.